Newsmakers: Tekmira Pharmaceuticals, Repros Therapeutics, Edap Tms SA, Covidien, Pfizer Print
Thursday, 28 August 2014 14:58

U.S. stocks slide from record highs moderately on Thursday following Ukraine's president said Russian forces had been brought into his country, returning focus to the volatile region, though the latest round of U.S. economic data pointed to improving conditions.

Worries over tension abroad had largely faded from Wall Street, with major indexes seeing few negative days over the past two weeks and both the Dow and S&P hitting records.

 

Shares of Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) picked up momentum again and gained 7%. Longs have had a solid ride this year. Prices peaked at $31.48 on mid March, round-tripped back down to $8.86 on July 17 and jumped to $26.05 on August 11.

Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) are among the biggest winners and soared 18% to $21.50. Today’s up move was after the company reported a successful results in a Phase 3 clinical trial comparing its secondary hypogonadism treatment Androxal (single isomer of clomiphene citrate) to Abbvie's (NYSE:ABBV) Androgel (testosterone gel) and placebo.

Edap Tms SA (ADR)(NASDAQ:EDAP) fell over 4% after the company said that it lost 5.30 million euros in the second quarter on revenue of 5.60 million euros. Operating loss stood at 1.60 million euros. On the per share basis, the company lost 23 cents.

Covidien (NYSE:COV) acquired privately-held North Carolina-based Sapheon for an unrevealed amount. Sapheon's lead product is the CE-Marked VenaSeal system for the treatment of varicose veins and chronic venous insufficiency. In addition to the EU, it is approved for sale in Canada and Hong Kong.

The FDA designates Pfizer's (NYSE:PFE) investigational Costridium difficile (C. difficile) vaccine candidate, PF-06425090, Fast Track. The Phase 2-stage product candidate is designed to prevent C. difficile-associated disease.




BiomedReports is not paid or compensated by newswires to disseminate or report news and
developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and

Error. Page cannot be displayed. Please contact your service provider for more details. (12)

investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.


Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
  BMR:1